Stephanie LaBomascus, MD
Triple-negative breast cancer (TNBC) is a heterogenous disease that is diagnosed in the absence of HER2 and hormone receptors. Though it has been difficult to identify a specific target for such a heterogenous disease, several therapeutic classes are showing great promise.
“Molecular profiling has revealed an unexpectedly high amount of heterogeneity as well as some common features within TNBC,” said Stephanie LaBomascus, MD, in a presentation during the 2019 OncLive®
State of the Science Summit™ on Breast Cancer.
“It’s unlikely we’re going to find a one-size-fits-all approach,” she added. “Understanding the fundamental differences in these tumors, and their biology is the first step in the development of targeted therapies for these patients.”
... to read the full story